Isa ga babban shafi

EU na nazari kan shirin bada damar soma amfani da rigakafin Coronavirus

Hoton kwalba mai dauke da alluran rigakafin cutar coronavirus da hadin gwiwar kamfanonin Pfizerda BioNTech suka samar.
Hoton kwalba mai dauke da alluran rigakafin cutar coronavirus da hadin gwiwar kamfanonin Pfizerda BioNTech suka samar. JOEL SAGET / AFP
Zubin rubutu: Nura Ado Suleiman | Ahmed Abba
Minti 2

Hukumar dake kula da samar da magunguna ta Turai ta ce, a ranar 29 ga watan Disamba za ta yanke shawara kan ko za ta baiwa hadin guiwar kamfanonin Pfizer da BioNTech da suka samar da rigakafin annobar coronavirus damar fara amfani da maganin a matakin gaggawa, kamar yadda takwaransu na Moderna ya gabatar da bukatar bashi irin damar.

Talla

Hukumar samar da magungunan ta Turai ta tabbatar da cewa ta karɓi bukatar a hukumance, daga kamfanonin harhada magunguna da suka samar da allurar rigakafin cutar coronavirus.

Hukumar dake da cibiya a Amsterdam tace, Idan bayanan da kamfanonin Pfizer na kasar Amurka da takwaransa BioNTech na Jamus suka gabatar ya tabbatar da ingancin rigakafin, za ta amince da shi, yayin babban taro da za ta gudanar a ranar 29 ga wannan wata na Disamba.

Yayin da kuma makamancin taron da zai gudana ranar 12 ga watan Janairu na shekarar 2021 mai kamawa, zai fayyace matsayin rigakafin cutar da kamfanin Moderna ya gabatar.

Gwaje-gwajen asibiti da aka yi kan wadannan magungunan rigakafin da kamfanonin suka samar a watan da ya gabata, ya nuna ingancin allurar rigakafin da kusan kashi 95 cikin 100.

LabaranSamun Labaran RFI, Hirarraki, Rubattattuun Labarai, Labarai game da wani, shirye-shirye.

Babu shafi

Babu bayanan da ka bukata ko kuma sam babu su.